The global high pressure contrast media injectors market is anticipated to grow at a CAGR of around 11.8% during the forecast period 2021 to 2028 and to reach around US$ 211.4 Million by 2028.
|Market||High Pressure Contrast Media Injectors (HPCMI) Market|
|Analysis Period||2017 - 2028|
|Forecast Data||2021 - 2028|
|Segments Covered||By Type, By Product, By Application, By End Use, and By Region|
|Regional Scope||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa|
|Key Companies Profiled||
Bracco Group, Ulrich GmbH & Co. KG, Sino Medical-Device Technology Co., Guerbet Group, Medtron AG, Bayer, NemotoKyorindo Co., Ltd., GE Healthcare, Apollo RT Co. Ltd.
||Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis|
|Customization Scope||10 hrs of free customization and expert consultation|
HPCMIs are devices that are used to inject contrast media into the body in order to enhance the visibility of tissues during medical imaging examinations. The rising prevalence of cancer and cardiovascular disease, as well as the high number of contrast agent approvals, and the increasing investments, money, and grants made by government organisations, all contribute to the growth of high pressure contrast media injectors market. High pressure contrast media injectors have progressed from manual injectors with stop-cocks to automated ones as technology has advanced. These technologies improve accuracy and provide a number of benefits. The integration of sophisticated technologies with traditional high pressure contrast media injectors is driving the market. This section discusses IT-enabled syringeless and high-pressure automated injectors. In recent years, syringeless power injectors have gained popularity as a means of reducing contrast media waste. Furthermore, syringeless injectors have been shown to reduce exam times, resulting in higher patient turnover. On the other hand, the high cost of high pressure contrast media injectors, consumables, and accessories is limiting market growth. As artificial intelligence makes its way into the healthcare industry, manufacturers of high pressure contrast media injectors are focusing their efforts on developing intelligent equipment that reduces the possibility of human error. Interface systems such as the Radiology Information System (RIS) and the Picture Archive and Communication System (PACS) aid in the collection of patient data and the administration of the required amount of contrast. Bracco Group Company has developed one-of-a-kind high pressure contrast media injectors for intravenous operations in CT and MRI to maximise smart technology penetration.
The CT Injector Systems segment of the Injectors Market is expected to grow rapidly
Since CT system usage has increased in recent years, CT injectors are expected to grow favorably, and these CT systems include a dual-head injector with two syringes for initial and follow-up contrast dosages during imaging. Major academic institutions and pharmaceutical companies have been conducting ongoing research and development to create procedures that help CT users take advantage of the increased capabilities of modern imaging equipment. During the forecast period, IT integration and contrast media dosage control are expected to be significant growth drivers due to involvement of advanced technology.
CT scanner and automated contrast injector manufacturers are working together to improve system integration. This entails keeping track of the contrast dosage. In 2016, Mallinckrodt, Pharmaceutical’s registered OptiSync data management system, which is designed to collect and analyze radiology data obtained during a contrast-enhanced CT imaging session.
All of these elements are likely to contribute to the market's positive growth during the forecast period.
North America to Dominate the Market
North America is the largest market for high pressure contrast media injectors, and the US, Canada, and Mexico are the major contributors to the market in this region. The growth of the North American market is characterized by the growing prevalence of cancer and corresponding growth in cancer diagnostic tools, technological advancements in high pressure contrast media injectors techniques and rising geriatric population. In addition, growing healthcare expenditure is likely to be a major growth stimulator for the high pressure contrast media injectors market in North America.
Substantial prevalence of chronic conditions such as cancer, cardiac conditions, neurological conditions, diabetes, and orthopedic conditions are expected to drive the adoption of medical second opinion services. For instance, according to a data published by Epilepsy Canada in 2019, an estimated 15,000 people in Canada suffer from epilepsy each year. Such extensively increasing prevalence of disease is prominently estimated to drive the adoption of advanced medical devices to manage the diseases and to improve treatment outcomes.
Major players in this industry are coming forward to consolidate the market position of high pressure contrast media injectors market. These players are responsible to increase access to healthcare professionals and increasing the awareness about benefits of medical devices globally.
Developing healthcare infrastructure, along with increasing investments in research & development and increasing product launches are anticipated to drive the Mexico high pressure contrast media injectors market during the forecast period. Further, the exponentially increasing prevalence of chronic conditions is also estimated to offer lucrative opportunities for the growth of the market during the forecast period.
Europe register a robust growth rate over the forecast period
The Europe high pressure contrast media injectors market includes major countries such as Germany, France, the United Kingdom, Italy, and Rest of Europe. Europe occupies a significant position in the global high pressure contrast media injectors market and is estimated to register a robust growth rate over the forecast period. The market growth in the region is expected due to the increasing demand for medical devices, growing research, and development in the field of medical technology, and rising numbers of hospitals that are dedicated geriatric population.
COVID 19 Impact
North American area is heavily affected owing to the emergence of Covid-19 pandemic. Countries such as the US and Canada reported the greatest number of COVID-19 positive cases. The US-registered greatest number of fatalities attributable to the COVID-19 epidemic. The chaotic scenario was produced in the medical sector throughout the country, increased demand for diagnostic and treating gadgets have significantly grown in the hospitals. For instance, demand for ventilators, respirators, and in-vitro diagnostic (IVD) testing has grown significantly in hospitals throughout the countries. On the other hand, demand for personal protection kits has substantially gone up.
The FDA has increased its efforts to support the health of people and have imposed several guidelines for hospitals and medical device companies. Various companies such as Guerbet Group enhanced their research and development activities for diagnostics tests and therapeutic devices. Thus, increased production by the companies has resulted in profits, and the outbreak of COVID-19 has shown a positive impact on market growth.
High Pressure Contrast Media Injectors Market Segment Analysis, 2020
The global high pressure contrast media injectors market is segmented into type, product, application, and end use. The type segment is divided into below single head injectors, dual head injectors, and syringeless injectors. The product segment is bifurcated into Injector Systems and Consumables. The application segment is bifurcated into interventional cardiology, endovascular surgery, interventional neuroradiology, and interventional radiology. The end use segment is bifurcated into hospitals, ambulatory surgical centers (ASCs), diagnostic centers. Players operating in the global high pressure contrast media injectors market are Bracco Group, Ulrich GmbH & Co. KG, Sino Medical-Device Technology Co., Guerbet Group, Medtron AG, Bayer, NemotoKyorindo Co., Ltd., GE Healthcare, Apollo RT Co. Ltd.
Market By Type:
Market By Product:
Market By Application:
Market By End Use:
Market By Region
The global high pressure contrast media injectors market in 2028 is expected to be above US$ 211.4 Million.
The CAGR of the global high pressure contrast media injectors market from 2021-2028 is above 11.8%.
The primary driver driving the market's growth is the rising prevalence of cancer and cardiovascular disease, as well as the high number of contrast agent approvals, and the increasing investments, money, and grants made by government organisations.
Hospital segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Guerbet Group and Medtron AG.
The North America is expected to account for significant revenue share in the global market.